What do analysts think about ALZN?

**No Analysts Currently Cover ALZN**.

1. **No Analyst Coverage**: There are no analysts currently providing coverage for Alzamend Neuro (ALZN) as indicated by the absence of any analyst ratings or price targets in the references.
2. **Recent Developments**: The most recent developments include a partnership with Massachusetts General Hospital for a Phase II clinical trial of AL001 for PTSD treatment, a Phase II clinical trial for AL001, a reverse stock split, and an extension for Nasdaq listing. These developments suggest potential growth opportunities, but they do not necessarily attract analyst coverage as they do not necessarily translate to financial projections or earnings estimates that analysts use to rate stocks.

In conclusion, due to the lack of analyst coverage, it is not possible to provide an analysis of what analysts think about ALZN.